Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List
Cancers · 18.07.2025 · 17 (14) · 2388
DOI: 10.3390/cancers17142388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.07.2025. Verfasst von Ilaria Attili und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, European Institute of Oncology, IEO, IRCCS, 20141 Milan, Italy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Worldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) including up to 80–85% of all lung cancer diagnoses. The landscape of NSCLC is characterized by a heterogeneous spectrum of gene alterations, with tyrosine kinase inhibitors (TKIs) and targeted treatments that significantly improve survival outcomes for patients with oncogene-addicted NSCLC, offering superior efficacy, and often favorable safety and tolerability profiles compared to chemotherapy-based treatments. However, the complexity of NSCLC extends to co-occurring genomic alterations or amplifications in tumor suppressors and other oncogenes, such as TP53, STK11, KEAP1, PIK3CA, RB1, and others, that significantly influence disease progression, therapeutic resistance, and clinical outcomes. These co-mutations often contribute to the development of primary and acquired resistance to targeted therapies, complicating decision-making strategies. This review provides a timely and comprehensive synthesis of current insights into co-mutations in NSCLC, with a particular focus on their clinical implications, and offers a novel perspective by integrating recent molecular insights with therapeutic challenges, addressing existing knowledge gaps through a more integrative and clinically oriented analysis of co-mutations. Advances in next-generation sequencing (NGS) and molecular profiling have enabled the identification of these co-alterations, paving the way for more personalized therapeutic approaches. However, challenges remain in interpreting the functional interplay of co-mutations and translating these insights into effective clinical interventions. This review also highlights the significance of co-mutations in shaping NSCLC biology, and discusses their impact on current therapeutic paradigms, emphasizing the need for integrative biomarker-driven approaches to improve outcomes in NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thoracic Oncology, European Institute of Oncology, IEO, IRCCS, 20141 Milan, Italy.
- Department of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.
ORCID-Profile: Ilaria Attili, Federico Pio Fabrizio
Zitieren
APA
Attili, I., Fabrizio, F. P., & Marinis, F. (2025). Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List. Cancers, 17(14), 2388. https://doi.org/10.3390/cancers17142388
Vancouver
Attili I, Fabrizio FP, Marinis F. Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List. Cancers. 2025;17(14):2388. doi:10.3390/cancers17142388
BibTeX
@article{Attili2025,
author = {Attili, Ilaria and Fabrizio, Federico Pio and Marinis, Filippo de},
title = {Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List},
journal = {Cancers},
year = {2025},
volume = {17},
number = {14},
pages = {2388},
doi = {10.3390/cancers17142388}
}
EUVIMED